IN8bio (NASDAQ:INAB) versus Quince Therapeutics (NASDAQ:QNCX) Head to Head Review

IN8bio (NASDAQ:INAB) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares IN8bio and Quince Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.75)	-0.33
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.20

Quince Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for IN8bio and Quince Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	2	0	3.00
Quince Therapeutics	0	0	4	2	3.33

IN8bio currently has a consensus price target of $7.75, indicating a potential upside of 3,014.95%. Quince Therapeutics has a consensus price target of $9.50, indicating a potential upside of 537.58%. Given IN8bio’s higher probable upside, equities research analysts clearly believe IN8bio is more favorable than Quince Therapeutics.

Insider & Institutional Ownership

92.1% of IN8bio shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares IN8bio and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-197.15%	-130.48%
Quince Therapeutics	N/A	-53.27%	-22.73%

Volatility and Risk

IN8bio has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

Quince Therapeutics beats IN8bio on 7 of the 12 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.